Literature DB >> 315977

Karyotype studies of cutaneous T cell lymphoma: evidence for clonal origin.

R L Edelson, C L Berger, J Raafat, D Warburton.   

Abstract

Neoplastic lymphocytes from 3 patients with widespread cutaneous T cell lymphoma were karyotyped, using a chromosome banding technique. None of the patients had previously received chemotherapy. Morphologically homogeneous populations of abnormal T cells were available from 2 distinct body regions of 2 of the individuals and from the bone marrow of the third. Karyotypes from each of the 3 patients indicated monoclonality of their lymphoma. These observations suggest that extracutaneous dissemination of cutaneous T cell lymphoma involves spread of neoplastic cells derived from a single clone. If future studies can demonstrate that those neoplastic T cells actually localized in the skin are also progeny of a single malignant cell, a widely accepted concept that cutaneous T cell lymphoma is of multifocal origin will have to be reexamined.

Entities:  

Mesh:

Year:  1979        PMID: 315977     DOI: 10.1111/1523-1747.ep12541543

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  3 in total

1.  Dual genotype in cutaneous T-cell lymphomas and pseudolymphomas.

Authors:  Y J Bignon; P Souteyrand; H Roger; D Bernard; B Dastugue; F Ramos; M d'Incan; P Chollet; R Plagne
Journal:  Hum Genet       Date:  1990-01       Impact factor: 4.132

2.  Diagnosis of cutaneous T cell lymphoma by use of monoclonal antibodies reactive with tumor-associated antigens.

Authors:  C L Berger; S Morrison; A Chu; J Patterson; A Estabrook; S Takezaki; J Sharon; D Warburton; O Irigoyen; R L Edelson
Journal:  J Clin Invest       Date:  1982-12       Impact factor: 14.808

3.  Improved generation of anti-tumor immunity by antigen dose limitation.

Authors:  Joshua D Shofner; Juan G Vasquez; Carole L Berger; Richard L Edelson
Journal:  J Immune Based Ther Vaccines       Date:  2007-02-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.